Samsung Biologics (KRX: 207940.KS), a publicly-traded biotechnology company, is opening its first US CDO (contract diagnostic organisation) R&D Centre in San Francisco, it was reported on Wednesday.

With its new facility, the firm intends to maximise client satisfaction and offer immediate convenience to biotech companies in the Bay area.

The company is to offer real-time interaction and be in closer proximity to potential and present customers in the region. The new facility is to use the same CDO research and development capabilities present at the company's headquarters in Incheon, South Korea.